b'REDUCING PAIN ANDCANCER RISK FOR WOMEN EXIMIS SURGICALSince 2014, minimally invasive laparoscopicinfection risk, shorten hospital stays, reduce surgeries to perform hysterectomies andcomplications, save on health care costs, and remove uterine fibroids (myomectomies)help patients recover more quickly.may require surgeons to increase an incisionThe first OEDIT grant helped prove the systems significantly from the small entry points forconcept, advance product development, and the laparoscopic tools and camera. Thatscreate control algorithms. The second fueled because, that year, the U.S. Food and Drugmanufacturing scale-up, clinical study support, Administration issued a warning on the risksand market development, Ford-Serbu says.of power morcellators in spreading cancer in the abdomen. Eximis Surgical was foundedWe utilized the grant to progress our product with the idea of a product to avoid thatdevelopment and to help us really gain an increased incision and the risks uncontainedunderstanding of tissue types and tissueDonna Ford-Serbu, Co-Founder and CEO, Eximis Surgicalspecimen removal posed. characterization, she says. It really was helpful in offsetting some of our costs during Two state-funded awards, one for $150,000development.in 2016 and a $250,000 grant in 2019, helped move that product from concept to proto- Eximis expects to launch a small clinical trial type, says Donna Ford-Serbu, the 10-person,in pursuit of FDA de novo approval in earlyWe utilized the Louisville-based companys CEO.2024, Ford-Serbu says. The $8.7 million series The Eximis Lap Specimen Removal PlatformB funding round the company closed in Marchgrant to progress 2023 will support that.uses radiofrequency cutting wires and multi-lay- Weve got a great opportunity and a clinicalour productered containment bags to segment large spec-imens so surgeons can maintain a smaller inci- need to serve in front of us, Ford-Serbu says.development andsion for specimen removaland thus reduceWere excited to get our solution to market. to help us really gain Eximis Surgical advanced product development with OEDIT support an understandingof tissue types and tissue characterization.DONNA FORD-SERBU Co-Founder and CEO Eximis Surgical38 BIOSCIENCE COLORADO 2023-2024'